[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"restenoses-coronary\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:restenoses-coronary":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,53],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100406533","abbott-vascular-medical-device-registry-100406533",false,"NCT04573660","Abbott Vascular Medical Device Registry","AV-MDR","Inclusion Criteria:\n\n1. Subject is at least 18 years of age.\n2. Subject has a planned procedure, or underwent a procedure, that will use\u002Fused one or more Abbott target devices covered in this registry.\n3. Subject is willing and able to comply with, or has already completed, the follow-up schedule specified in this protocol.\n4. Subject must provide written informed consent prior to any clinical investigation-related data collection or be enrolled under an IRB\u002FEC approved waiver of consent.\n\nExclusion Criteria:\n\n1\\. Subject has active symptoms and\u002For a positive test result of COVID-19 or other rapidly spreading novel infectious agent within the prior 2 months of the date of procedure.","ALL","18 Years",{"count":19,"type":20},3784,"ESTIMATED","OBSERVATIONAL","The AV-MDR is a prospective, non-randomized, open-label, multi-center registry. The purpose of the AV-MDR study is to proactively collect and evaluate clinical data on the usage of the devices in scope within their intended use with the aim of confirming safety and performance throughout their expected lifetime, ensuring the continued acceptability of identified risks, detecting emerging risks on the basis of factual evidence, ensuring the continued acceptability of the benefit-risk ratio, and identifying possible systematic misuse or off-label usage such that the intended use can be verified as appropriate.",[24,25,26,27,28],"Acute Myocardial Infarction","Restenoses, Coronary","Coronary Artery Lesions","Venous Embolism","Arterial Embolism",[30,31,32,33,34,35,36,37,38,39],"Coronary and peripheral stents","ABT-CIP-10349","Vascular plugs","Pacing catheters","Measurement and imaging (FFR and OCT)","Peripheral dilatation catheters","Coronary dilatation catheters","Coronary and peripheral guidewires","Vessel closure\u002Fcompression devices","Vascular access introducers","RECRUITING","2025-07-01",{"date":43,"type":44},"2025-07-03","ACTUAL",{"date":46,"type":44},"2020-10-25",{"date":48,"type":20},"2031-11",{"name":50,"class":51},"Abbott Medical Devices","INDUSTRY",37,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100481120","intracoronary-stenting-and-restenosis---randomized-trial-of-drug-eluting-stent-implantation-or-drug-coated-balloon-angioplasty-according-to-neointima-morphology-in-drug-eluting-stent-restenosis-5-100481120","NCT05544864","Intracoronary Stenting and Restenosis - Randomized Trial of Drug-eluting Stent Implantation or Drug-coated Balloon Angioplasty According to Neointima Morphology in Drug-eluting Stent Restenosis 5","ISAR-DESIRE5","Inclusion Criteria:\n\n1. Patients with ischemic symptoms and\u002For evidence of myocardial ischemia\n2. Presence of ≥ 50% restenosis after prior implantation of drug-eluting stents in native coronary vessels.\n3. Availability of an OCT-pullback of the target lesion\n4. Written informed consent by the patient for participation in the study.\n5. Age ≥ 18 years\n\nExclusion Criteria:\n\n1. Cardiogenic shock\n2. Acute ST-elevation myocardial infarction within 48 hours from symptom onset.\n3. Target lesion located in left main trunk or bypass graft.\n4. Additional coronary intervention planned within 30 days of the procedure.\n5. Non-successful treatment of other lesion(s) during the same procedure\n6. Severe renal insufficiency (glomerular filtration rate ≤ 30 ml\u002Fmin)\n7. Contraindications to any components of the investigational devices or dual antiplatelet therapy\n8. Pregnancy (present, suspected or planned) or positive pregnancy test.\n9. Previous enrollment in this trial or participation in any other study at the time of enrollment.\n10. Malignancies or other comorbid conditions with life expectancy less than 12 months or that may result in protocol non-compliance.\n11. Patient's inability to fully comply with the study protocol",{"count":61,"type":20},376,"INTERVENTIONAL",[64],"NA","The hypothesis of the study is, that there is a significant interaction in treatment effect between the OCT pattern of neointima (heterogeneous or homogeneous) and the type of percutaneous coronary intervention (drug-eluting stent or drug-coated balloon) in patients with in-stent restenosis.",[67,25],"Coronary Artery Disease","2025-01-03",{"date":70,"type":44},"2025-01-06",{"date":72,"type":44},"2022-09-28",{"date":74,"type":20},"2026-09",{"name":76,"class":77},"Deutsches Herzzentrum Muenchen","OTHER",5]